<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03529253</url>
  </required_header>
  <id_info>
    <org_study_id>290068</org_study_id>
    <nct_id>NCT03529253</nct_id>
  </id_info>
  <brief_title>Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound</brief_title>
  <acronym>ANTARES</acronym>
  <official_title>Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kobe University</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kobe University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify whether additional administration of Alirocumab exerts&#xD;
      a stronger stabilizing effect on the vulnerable plaque in CAD, compared with statin alone&#xD;
      administration in patients receiving PCI. Therefore, the change in maxLCBI (4 mm) of the&#xD;
      coronary artery 9 months after administration by addition administration of Alirocumab is&#xD;
      evaluated as the main evaluation item as compared with statin administration alone for&#xD;
      patients who have CAD and received PCI. Also, change of plaque properties is compared with&#xD;
      baseline and evaluated. This study is a single-center, randomized, open-label study, using&#xD;
      alirocumab, rosuvastatin as test drugs. Based on the findings obtained in this study, it is&#xD;
      possible to clarify the mechanism of stabilization of the plaque in a patient with coronary&#xD;
      artery disease, which in turn suppresses the progress of plaque in coronary artery disease,&#xD;
      resulting in primary or secondary There is a possibility that it can contribute to&#xD;
      prevention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators investigate the change in the maxLCBI (4 mm) value calculated by NIRS-IVUS&#xD;
      at the time of PCI and at the treatment evaluation after 9 months compared with the group of&#xD;
      Alirocumab(Alirocumab75mg/2week+losuvastatin10mg/daily) and standard treatment&#xD;
      (losuvastatin10mg/daily alone). And also the investigators evaluate LCBI(lesion), Angle of a&#xD;
      lipid core, EEM CSA, Lumen CSA, Minimum lumen diameter, Plaque burden, Lesion length by&#xD;
      NIRS-IVUS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maxLCBI (4mm)</measure>
    <time_frame>baseline and 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change amount of LCBI(lesion)</measure>
    <time_frame>baseline and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change amount of Angle of lipid core</measure>
    <time_frame>baseline and 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change amount of LDL-Cholesterol level</measure>
    <time_frame>baseline and 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Intensive therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab group is Alirocumab75mg/2week plus Rosuvastatin10mg/daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The standard therapy group is Rosuvastatin10mg/daily alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily</intervention_name>
    <description>Alirocumab group receive Alirocumab75mg/2week subcutaneous injection plus Rosuvastatin10mg/daily by oral for 9 months.</description>
    <arm_group_label>Intensive therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin calcium10mg</intervention_name>
    <description>Rosuvastatin10mg/daily by oral for 9 months.</description>
    <arm_group_label>Standard therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who underwent PCI for ACS or stable coronary heart disease&#xD;
&#xD;
          -  Patients with LDL-C ≥70 mg/dL under daily 10mg rosuvastatin&#xD;
&#xD;
          -  Patients who remained 25-75% stenosis with coronary angiography&#xD;
&#xD;
          -  Patients who obtained analyzable images and calculated maxLCBI (4 mm) with NIRS-IVUS&#xD;
&#xD;
          -  Patients aged ≥20 years old at PCI&#xD;
&#xD;
          -  Patients who agree to be enrolled in the trial give signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have been treated previously with at least one dose of any anti-PCSK9&#xD;
             monoclonal antibody&#xD;
&#xD;
          -  Patients had uncontrolled hypertension (systolic blood pressure &gt;180 mmHg or diastolic&#xD;
             blood pressure &gt;110 mmHg) between the time of PCI and randomization visit&#xD;
&#xD;
          -  Known hypersensitivity to alirocumab or rosuvastatin&#xD;
&#xD;
          -  All contraindications to alirocumab and/or rosuvastatin as displayed in the respective&#xD;
             national product labeling for these treatments&#xD;
&#xD;
          -  Known history of hemorrhagic stroke&#xD;
&#xD;
          -  Currently under treatment for cancer&#xD;
&#xD;
          -  Patients on lipoprotein apheresis&#xD;
&#xD;
          -  Patients with severe liver or renal dysfunction&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patients recognized as inadequate by attending physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hiromasa Otake, MD, PhD</last_name>
    <phone>078-382-5846</phone>
    <email>hotake@med.kobe-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kobe University Graduate School of Medicine, Department of Cardiology</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiromasa Otake, MD</last_name>
      <phone>+81783825846</phone>
      <email>hotake@med.kobe-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>May 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kobe University</investigator_affiliation>
    <investigator_full_name>Hiromasa Otake</investigator_full_name>
    <investigator_title>senior lecturer</investigator_title>
  </responsible_party>
  <keyword>Alirocumab</keyword>
  <keyword>NIRS-IVUS</keyword>
  <keyword>LCBI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

